NKGen Biotech, Inc.: Nasdaq/NYSE listing notice — NKGen Biotech receives Nasdaq non-compliance notice for MVPHS below $15M

NKGen Biotech, Inc.

Received Nasdaq notice on Dec 2, 2024: market value of publicly held shares below $15M requirement.
Has 180 calendar days (until June 2, 2025) to regain compliance by closing at $15M+ for 10 consecutive business days.
No immediate effect on listing; company may consider available options to regain compliance.
If not regained, Nasdaq will issue delisting notice; company may appeal but no assurance of success.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

NKGen Biotech, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(C)

Exact text from the filing

December 2, 2024, NKGen Biotech, Inc. (the “ Company ”) received written notice (the “ MVPHS Notice ”) from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC (“ Nasdaq ”) notifying the Company that, based on the market value of publicly held shares for the previous 30 consecutive business days, the Company is not in compliance with Nasdaq Listing Rule 5450(b)(2)(C), which requires the Company’s listed securities to maintain a minimum market value of publicly held shares of $15,000,000 (the “ MVPHS Requirement ”). The MVPHS Notice has no immediate effect on the listing of the Com

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-24-105644

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.